Worth Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$469K Buy
1,863
+237
+15% +$51K 0.15% 120
2026
Q1
$354K Buy
1,626
+102
+7% +$22.6K 0.13% 134
2025
Q4
$348K Sell
1,524
-226
-13% -$51.5K 0.15% 102
2025
Q3
$405K Buy
1,750
+194
+12% +$39.5K 0.18% 89
2025
Q2
$289K Sell
1,556
-6,533
-81% -$1.21M 0.14% 107
2025
Q1
$1.69M Buy
8,089
+6,573
+434% +$1.28M 0.93% 26
2024
Q4
$269K Sell
1,516
-9,714
-87% -$1.79M 0.14% 110
2024
Q3
$2.22M Buy
11,230
+9,714
+641% +$1.81M 1.21% 18
2024
Q2
$260K Sell
1,516
-225
-13% -$37.3K 0.15% 103
2024
Q1
$317K Hold
1,741
0.2% 83
2023
Q4
$270K Hold
1,741
0.19% 83
2023
Q3
$260K Sell
1,741
-77
-4% -$11.3K 0.21% 79
2023
Q2
$245K Buy
1,818
+77
+4% +$11.3K 0.19% 72
2023
Q1
$277K Sell
1,741
-83
-5% -$12.7K 0.21% 64
2022
Q4
$295K Sell
1,824
-6
-0.3% -$920 0.21% 58
2022
Q3
$245K Sell
1,830
-503
-22% -$72.2K 0.18% 46
2022
Q2
$357K Sell
2,333
-299
-11% -$45.7K 0.24% 52
2022
Q1
$407K Buy
+2,632
New +$382K 0.27% 47

Other funds holding ABBV

Worth Asset Management's ABBV Position: Q2 2026 in Review

Worth Asset Management increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $51K and bringing the position to 1,863 shares worth $469K. The position accounts for 0.15% of the portfolio, ranked #120.

Worth Asset Management first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.22M in Q3 2024. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Worth Asset Management held 1,863 shares of AbbVie worth $469K as of Q2 2026.
  • Worth Asset Management bought 237 AbbVie shares in Q2 2026, an estimated $51K.
  • AbbVie made up 0.15% of Worth Asset Management's portfolio in Q2 2026, its #120 holding.
  • Worth Asset Management first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
  • Worth Asset Management's AbbVie position peaked at $2.22M in Q3 2024.
  • 803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Worth Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.